Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Moja, Lorenzo, Lucenteforte, Ersilia, Kwag, Koren H, Bertele, Vittorio, Campomori, Annalisa, Chakravarthy, Usha, D'Amico, Roberto, Dickersin, Kay, Kodjikian, Laurent, Lindsley, Kristina, Loke, Yoon, Maguire, Maureen, Martin, Daniel F, Mugelli, Alessandro, Mühlbauer, Bernd, Püntmann, Isabel, Reeves, Barnaby, Rogers, Chris, Schmucker, Christine, Subramanian, Manju L and Virgili, Gianni (2014) Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews, 9.

Full text not available from this repository. (Request a copy)

Abstract

Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby preventing its pathological angiogenesis. Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevacizumab is approved for intravenous use as a cancer therapy. However, due to the biological similarity of the two drugs, bevacizumab is widely used off-label to treat neovascular AMD.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 09 Oct 2014 16:10
Last Modified: 21 Apr 2020 23:29
URI: https://ueaeprints.uea.ac.uk/id/eprint/50486
DOI: 10.1002/14651858.CD011230.pub2

Actions (login required)

View Item View Item